{"entity":{"id":"paper-taylor-integrative-genomic-profiling-cancer-cell-2010","kind":"paper","name":"Integrative genomic profiling of human prostate cancer","aka":["Taylor 2010","MSKCC prostate genomics 218 tumours"],"tldr":"The first large look at prostate cancer across copy number, gene expression and sequence at once. Its most useful finding for patients was that the pattern of gained and lost chromosome segments separates low-risk from high-risk disease better than the Gleason score does.","summary":"Barry Taylor, Charles Sawyers, William Gerald and colleagues at Memorial Sloan Kettering assessed DNA copy number, messenger RNA expression and focused exon resequencing concordantly in 218 prostate tumours, and released the genomic and clinical outcome data as a public resource.\n\nTwo results stand out. NCOA2, a nuclear receptor coactivator, behaved as an oncogene in around 11 percent of tumours, extending the androgen receptor pathway beyond the receptor itself. And copy-number alterations in primary tumours defined clusters of low-risk and high-risk disease beyond what the Gleason score achieved, which is the intellectual origin of the commercial genomic classifiers now used to decide who needs radical treatment.","asOf":"2026-09-25","links":[{"label":"Cancer Cell 2010","url":"https://doi.org/10.1016/j.ccr.2010.05.026"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/20579941/"}],"tags":["prostate-evidence"],"related":["paper-tomlins-tmprss2-ets-fusion-science-2005","paper-grasso-mutational-landscape-lethal-crpc-nature-2012","paper-esteva-npj-digit-med","prostate-roadmap"],"cancers":["prostate","prostate-high-risk"],"sections":["diagnostics","ai-computation"],"technologies":["cgp"],"targets":["erg","tmprss2","androgen-receptor","ncoa2"],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":["ar-signaling","chromosomal-instability","prostate-cancer-signalling"],"terms":["gleason-grade-group","ngs","copy-number-variation-term","gene-fusion"],"trials":[],"people":["charles-sawyers"],"bottlenecks":["b-biomarker-validation","b-data-silos","b-tumor-heterogeneity"],"keyPapers":[],"journals":["cancer-cell"],"dependsOn":[],"notes":[],"journal":"Cancer Cell","year":2010,"doi":"10.1016/j.ccr.2010.05.026","pmid":"20579941","authors":"Taylor BS, Schultz N, Hieronymus H, et al.","paperType":"basic","findings":["Concordant DNA copy number, messenger RNA expression and focused exon resequencing in 218 prostate cancer tumours.","The nuclear receptor coactivator NCOA2 was identified as an oncogene in approximately 11 percent of tumours.","The androgen-driven TMPRSS2-ERG fusion was associated with a previously unrecognised prostate-specific deletion at chromosome 3p14, implicating FOXP1, RYBP and SHQ1 as potential cooperative tumour suppressors.","Copy-number data from primary tumours defined clusters of low-risk and high-risk disease beyond that achieved by Gleason score.","The genomic and clinical outcome data were released as a public resource."],"whatItMeans":"The origin of the idea that a prostate tumour's copy-number pattern carries prognostic information the pathologist's grade does not. That idea became Decipher and the other genomic classifiers, which are now used in some systems to decide whether a man needs radiotherapy after surgery.","caveats":["218 tumours, largely from one institution, with the referral pattern that implies.","Prognostic clustering derived and tested in the same cohort needs independent validation, which the commercial classifiers later supplied for their own signatures rather than for this one.","Focused exon resequencing rather than whole-exome, so the mutational picture is partial; Grasso and Baca filled it in."],"changedPractice":false,"participants":218},"route":"/key-papers/paper-taylor-integrative-genomic-profiling-cancer-cell-2010/","neighbours":{"paper":[{"id":"paper-esteva-npj-digit-med","kind":"paper","name":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials","route":"/key-papers/paper-esteva-npj-digit-med/"},{"id":"paper-tomlins-tmprss2-ets-fusion-science-2005","kind":"paper","name":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","route":"/key-papers/paper-tomlins-tmprss2-ets-fusion-science-2005/"},{"id":"paper-tcga-molecular-taxonomy-primary-prostate-cell-2015","kind":"paper","name":"TCGA: the molecular taxonomy of primary prostate cancer","route":"/key-papers/paper-tcga-molecular-taxonomy-primary-prostate-cell-2015/"},{"id":"paper-grasso-mutational-landscape-lethal-crpc-nature-2012","kind":"paper","name":"The mutational landscape of lethal castration-resistant prostate cancer","route":"/key-papers/paper-grasso-mutational-landscape-lethal-crpc-nature-2012/"}],"roadmap":[{"id":"prostate-roadmap","kind":"roadmap","name":"Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch","route":"/roadmaps/prostate-roadmap/"}],"cancer":[{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"},{"id":"erg","kind":"target","name":"ERG","route":"/targets/erg/"},{"id":"ncoa2","kind":"target","name":"NCOA2","route":"/targets/ncoa2/"},{"id":"tmprss2","kind":"target","name":"TMPRSS2","route":"/targets/tmprss2/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"pathway":[{"id":"ar-signaling","kind":"pathway","name":"Androgen receptor signalling","route":"/pathways/ar-signaling/"},{"id":"chromosomal-instability","kind":"pathway","name":"Chromosomal instability & aneuploidy","route":"/pathways/chromosomal-instability/"},{"id":"prostate-cancer-signalling","kind":"pathway","name":"Prostate cancer (KEGG map)","route":"/pathways/prostate-cancer-signalling/"}],"term":[{"id":"copy-number-variation-term","kind":"term","name":"Copy number alteration (CNA)","route":"/terms/copy-number-variation-term/"},{"id":"gene-fusion","kind":"term","name":"Gene fusion","route":"/terms/gene-fusion/"},{"id":"gleason-grade-group","kind":"term","name":"Gleason score / Grade Group","route":"/terms/gleason-grade-group/"},{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/"}],"person":[{"id":"charles-sawyers","kind":"person","name":"Charles L. Sawyers","route":"/people/charles-sawyers/"}],"bottleneck":[{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/"},{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/"},{"id":"b-tumor-heterogeneity","kind":"bottleneck","name":"Tumour heterogeneity and clonal evolution","route":"/bottlenecks/b-tumor-heterogeneity/"}],"journal":[{"id":"cancer-cell","kind":"journal","name":"Cancer Cell","route":"/journals/cancer-cell/"}]}}